
COGT Stock Forecast & Price Target
COGT Analyst Ratings
Bulls say
Cogent Biosciences is positioned for success with its focus on developing precision therapies for genetically defined diseases, particularly its program CGT9486 which has shown promising results in treating diseases caused by the KIT D816V mutation. With a strong emphasis on rational precision and addressing underlying causes, this innovative company shows potential for long-term growth and value creation. However, investors should be aware of potential risks such as negative clinical results or the emergence of superior competitor products which could impact valuation.
Bears say
Cogent Biosciences is facing a negative outlook due to its ongoing net losses and high R&D and SG&A expenses, leading to a projected full-year net loss increase for 2026. The company's financials show that it has a good amount of cash on hand, but the potential for M&A could be a distraction and may not solve their financial woes. With multiple regulatory timelines and data presentations coming up, the success of their lead program bezuclastinib is still uncertain, making it a risky investment at this time.
This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.
COGT Analyst Forecast & Price Prediction
Start investing in COGT
Order type
Buy in
Order amount
Est. shares
0 shares